UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Position in SVRA — Savara Inc

CIK 861177 NEW YORK, NY

Back to SVRA Full portfolio

Position in SVRA

as of Mar 31, 2026 · filed May 13, 2026 Compact

Position Value

$287,839

-$217,565 QoQ

Shares Held

52,718

-76.2% QoQ

Ownership

0.026%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#97

of 184 holders

Holding Since

Mar 2024

7 quarters on record

Voting authority Sole 52.70685534352593.ToString("F0")% Shared 0.ToString("F0")% None 47.29314465647407.ToString("F0")%

Common Shares in SVRA Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,287,605,812 across 211 Biotechnology names. SVRA ranks #147 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	3,057,396	$1,365,249,602
2	REGN	Regeneron Pharmaceuticals, Inc.	723,621	$559,098,523
3	ALNY	Alnylam Pharmaceuticals, Inc.	677,519	$224,170,706
4	INSM	INSMED Inc	1,215,025	$198,680,883
5	RPRX	Royalty Pharma plc	3,095,766	$148,503,890
6	INCY	Incyte Corp	1,540,913	$145,030,725
7	IONS	Ionis Pharmaceuticals Inc	1,475,632	$110,805,201
8	DNLI	Denali Therapeutics Inc.	4,432,314	$85,100,425

All Filings in SVRA

Export CSV

7 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$287,839	52,718	-76.2%	Shares	Defined	2026-05-13
2025-06-30	$505,404	221,669	+39.4%	Shares	Defined	2025-08-14
2025-03-31	$440,572	159,052	+1.3%	Shares	Defined	2025-05-19
2024-12-31	$481,935	156,983	+24.8%	Shares	Defined	2025-02-14
2024-09-30	$533,455	125,815	+5.1%	Shares	Defined	2024-11-14
2024-06-30	$482,285	119,674	+591.8%	Shares	Defined	2024-08-14
2024-03-31	$86,154	17,300	—	Shares	Defined	2024-05-15
No filing history on record for this holder in this stock.